Ionis Pharmaceuticals, Inc. reported significant financial results for the third quarter of 2025, with total revenue reaching $156.7 million, a 17% increase from $133.8 million in the same period of 2024. For the nine months ending September 30, 2025, total revenue was $740.4 million, compared to $478.6 million for the same period last year. The increase in revenue was primarily driven by the commercial launch of TRYNGOLZA, which generated $31.8 million in product sales during the quarter, alongside a rise in royalty revenues from SPINRAZA and WAINUA, which totaled $75.7 million for the quarter.

Despite the revenue growth, Ionis reported a net loss of $128.6 million for the third quarter, slightly improved from a net loss of $140.5 million in the same quarter of 2024. The nine-month net loss was $152.0 million, compared to $349.5 million for the same period last year. The company attributed the ongoing losses to increased operating expenses, which rose to $316.9 million for the quarter, up from $282.5 million in the prior year, largely due to higher selling, general, and administrative costs associated with the launches of new products.

Strategically, Ionis has made significant advancements in its product pipeline, launching DAWNZERA in August 2025, following FDA approval for the treatment of hereditary angioedema. The company is also advancing its late-stage pipeline, with several medicines in Phase 3 development, including ION582 for Angelman syndrome and eplontersen for transthyretin amyloidosis. The company’s collaboration with AstraZeneca for WAINUA continues to be a key focus, with AstraZeneca covering a significant portion of the development costs.

Operationally, Ionis has seen an increase in its employee headcount, reflecting its expansion efforts to support commercialization activities. The company reported cash and cash equivalents of $338.3 million as of September 30, 2025, up from $242.1 million at the end of 2024, providing a solid financial foundation for ongoing and future projects. Looking ahead, Ionis remains optimistic about its growth trajectory, with plans to launch additional medicines and expand its market presence, while continuing to manage its operational costs effectively.

About IONIS PHARMACEUTICALS INC

Ionis Pharmaceuticals is a biotech company specializing in RNA-targeted therapeutics. It develops and commercializes medicines for serious diseases across neurology, cardiology, and rare genetic disorders. Its core products include antisense and siRNA medicines, with a focus on genetic and neurodegenerative conditions. The company partners with global pharma firms, leveraging innovative technology to deliver life-changing treatments and generate revenue through product sales, royalties, and milestone payments.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.